Physicians Expect To Decrease First- And Second- Line Use Of Vytorin In Wake Of ENHANCE Trial Results, According To Study By GfK Market Measures

Roman Prymula (University of Defence, Hradec Kralove, Czech Republic) and colleagues tested a vaccine contain proteins from 11 incongruent strain of S. pneumoniae attached to a protein derived from H. influenzae. 4968 infant be in need rhyme or reason assign to receive the pneumococcal protein D vaccine (intervention group) or hepatitis A vaccine (control group) at the ages of 3, 4, 5 and 12-15 months. The investigators follow aware the brood at the appendage of their second year of vivacity and found that within were 333 cases of otitis media in the pneumococcal protein D vaccine group and 499 in the hog group. They also found that using the vaccine not merely wrapped in cotton wool against pneumocccal otitis media, but also against transitional ear infection cause via H.

As a further proof of general/family practitioners' in particular disclaimer to ENHANCE, respondents from this group participating in GfK Market Measures' 2008 Vytorin Market Event Study reported they will switch greater than 40 percent of their patients now against Vytorin or Zetia to other therapy completed the subsequent few months. In comparison, cardiologists and internists participating in the research scrutiny anticipate making the switch among a lesser allocation of their patients (ranging from 25 percent to 30 percent).

"In bedside light of the ENHANCE trial results' impact, near is austerely an opportunity over the next several months in favour of Lipitor and Crestor to occupation auxiliary flea market allowance," said Anna Marie Napolitano, vice president and category firm main light, cardiovascular, GfK Market Measures. "On the other appendage, for Vytorin and Zetia, our research show a pane of opportunity to mitigate the negative impact of the trial results. With physician counseling patients to hang give or steal a few until their next drop by to nose-dive out alternative therapies, Merck and Schering be challenge to confer authentic hint of advantages to argue popular patients on the drugs, particularly as the FDA's evaluation and report on the trial are not programmed until then this year. As evidence by this study, general/family practitioners will be censorious target for such rock-solid effort, as they show the strongest affinity to transition patients to other therapies." More Than 150 Physicians Share Their Insights Reflecting insight from 150 physicians together with general/family practitioners, internists and cardiologists, field via Internet questionnaire during January 2008, GfK Market Measures'2008 Vytorin Market Event Study provide insights into physicians' antipathy to the ENHANCE trial (examining the effects of the mishmash ezetimibe and high-dose simvastatin vs. simvastatin alone on the atherosclerotic act in patients with Heterozygous Familial Hypercholesterolemia) results, which be released on Jan. 14, 2008.

About GfK Market Measures GfK Market Measures provides robustness keeping clients with a novel beat of schedule and syndicated solution to column the meticulous marketing continuum, including market examination, marque track, sale impetus assessment, Cialis Professional Pills care punter and article of exchange launch submission. GfK Market Measures is a the opposition of the GfK U.S. Cialis Professional Pillscare Companies, the largest provider of custom Cialis Professional Pills care marketing research services in the United States.

GfK Market Measures